AU2021369508A1 - Pharmaceutical compositions and methods of using the same for treating cancer - Google Patents

Pharmaceutical compositions and methods of using the same for treating cancer Download PDF

Info

Publication number
AU2021369508A1
AU2021369508A1 AU2021369508A AU2021369508A AU2021369508A1 AU 2021369508 A1 AU2021369508 A1 AU 2021369508A1 AU 2021369508 A AU2021369508 A AU 2021369508A AU 2021369508 A AU2021369508 A AU 2021369508A AU 2021369508 A1 AU2021369508 A1 AU 2021369508A1
Authority
AU
Australia
Prior art keywords
effective amount
venetoclax
decitabine
cedazuridine
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021369508A
Other languages
English (en)
Inventor
Kim-Hien DAO
Harold Keer
Aram Oganesian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of AU2021369508A1 publication Critical patent/AU2021369508A1/en
Assigned to TAIHO PHARMACEUTICAL CO., LTD. reassignment TAIHO PHARMACEUTICAL CO., LTD. Request for Assignment Assignors: OTSUKA PHARMACEUTICAL CO., LTD.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021369508A 2020-10-29 2021-10-27 Pharmaceutical compositions and methods of using the same for treating cancer Pending AU2021369508A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063107010P 2020-10-29 2020-10-29
US63/107,010 2020-10-29
PCT/US2021/056809 WO2022093930A1 (en) 2020-10-29 2021-10-27 Pharmaceutical compositions and methods of using the same for treating cancer

Publications (1)

Publication Number Publication Date
AU2021369508A1 true AU2021369508A1 (en) 2023-03-02

Family

ID=81384423

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021369508A Pending AU2021369508A1 (en) 2020-10-29 2021-10-27 Pharmaceutical compositions and methods of using the same for treating cancer

Country Status (10)

Country Link
US (1) US20230405037A1 (https=)
EP (1) EP4237094A4 (https=)
JP (1) JP2023548303A (https=)
KR (1) KR20230097034A (https=)
CN (1) CN116018145A (https=)
AU (1) AU2021369508A1 (https=)
CA (1) CA3188316A1 (https=)
MX (1) MX2023003305A (https=)
TW (1) TW202227096A (https=)
WO (1) WO2022093930A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024229073A1 (en) * 2023-05-02 2024-11-07 Otsuka Pharmaceutical Co., Ltd. Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
SG11202108523UA (en) * 2019-03-25 2021-09-29 Otsuka Pharma Co Ltd Antitumor composition

Also Published As

Publication number Publication date
WO2022093930A1 (en) 2022-05-05
EP4237094A4 (en) 2024-07-10
US20230405037A1 (en) 2023-12-21
EP4237094A1 (en) 2023-09-06
TW202227096A (zh) 2022-07-16
CN116018145A (zh) 2023-04-25
MX2023003305A (es) 2023-04-13
KR20230097034A (ko) 2023-06-30
CA3188316A1 (en) 2022-05-05
JP2023548303A (ja) 2023-11-16

Similar Documents

Publication Publication Date Title
US11963971B2 (en) Combination decitabine and cedazuridine solid oral dosage forms
US8603521B2 (en) Formulations of histone deacetylase inhibitor and uses thereof
CA2845806C (en) Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
TWI694069B (zh) 治療精神分裂症之醫藥調配物
TW201103573A (en) Stable nanoparticulate drug suspension
CN104244952A (zh) 组蛋白脱乙酰酶抑制剂与帕唑帕尼的组合及其用途
JP2021514975A (ja) サイクリン依存性キナーゼ阻害剤およびｂｅｔ−ブロモドメイン阻害剤の組合せ
AU2021369508A1 (en) Pharmaceutical compositions and methods of using the same for treating cancer
HK40084686A (en) Pharmaceutical compositions and methods of using the same for treating cancer
CA3163122C (en) Combination decitabine and cedazuridine solid oral dosage forms
HK40121574A (en) Combination decitabine and cedazuridine solid oral dosage forms
HK40082478A (en) Solid oral dosage forms comprising decitabine and cedazuridine
HK40082478B (en) Solid oral dosage forms comprising decitabine and cedazuridine
EP4091614B1 (en) Method for stabilizing medicinal substance sensitive to humidity (dfp-11207), and stable preparation thereof
HK1200095B (en) Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAIHO PHARMACEUTICAL CO., LTD.

Free format text: FORMER APPLICANT(S): OTSUKA PHARMACEUTICAL CO., LTD.